FDA Finalizes Guidance on Co-Crystals in NDAs and ANDAs Post author:Sam Post published:February 14, 2018 Post category:Drug Industry Daily The FDA finalized new guidance establishing co-crystals as a drug product intermediate. Source: Drug Industry Daily You Might Also Like House to Vote on Budget Continuing Resolution as Early as Wednesday November 30, 2021 Form 483 Raises GMP Concerns About Apotek April 7, 2016 Drugmakers Back Sequenom’s Stance on Patent Eligibility April 6, 2016